10-K Filing

LifeMD, Inc. CIK: 948320 FY 2016

Filing Information

Form Type	10-K
Accession Number	`0001213900-17-005790`
Period End Date	20161231
Filing Date	20170524
Fiscal Year	2016
Fiscal Period	FY
XBRL Instance	immd-20161231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 55 Income Statement 40 Cash Flow Statement 64 Stockholders Equity 29

Balance Sheet 55 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Cash	`CashAndCashEquivalentsAtCarryingValue`	$73.86K	USD	Point-in-time
Cash	`CashAndCashEquivalentsAtCarryingValue`	$232.98K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	35.57M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	32.01M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	200,000.00	shares	Point-in-time
Cash	`CashAndCashEquivalentsAtCarryingValue`	$75.50K	USD	Point-in-time
Cash	`CashAndCashEquivalentsAtCarryingValue`	$182.56K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	434,782.00	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	32.01M	shares	Point-in-time
Trade accounts receivable, net	`AccountsReceivableNetCurrent`	$444.74K	USD	Point-in-time
Trade accounts receivable, net	`AccountsReceivableNetCurrent`	$154.44K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	35.25M	shares	Point-in-time
Treasury stock, common, shares	`TreasuryStockCommonShares`	-	shares	Point-in-time
Other receivables	`OtherReceivablesNetCurrent`	$2.25K	USD	Point-in-time
Treasury stock, common, shares	`TreasuryStockCommonShares`	325,000.00	shares	Point-in-time
Other receivables	`OtherReceivablesNetCurrent`	-	USD	Point-in-time
Inventory, net	`InventoryNet`	$160.27K	USD	Point-in-time
Inventory, net	`InventoryNet`	$61.05K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$448.47K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$789.82K	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$752.93K	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$167.48K	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	-	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$192.25K	USD	Point-in-time
Convertible notes payable	`ConvertibleNotesPayableCurrent`	$100.00K	USD	Point-in-time
Convertible notes payable	`ConvertibleNotesPayableCurrent`	-	USD	Point-in-time
Notes payable, net of discount	`NotesPayableCurrent`	$100.00K	USD	Point-in-time
Notes payable, net of discount	`NotesPayableCurrent`	$106.36K	USD	Point-in-time
Notes payable, net of discount	`NotesPayableCurrent`	$27.20K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$1.15M	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$267.48K	USD	Point-in-time
Common stock, $0.01 par value; 50,000,000 shares authorized, 35,570,157 and 32,010,375 shares issued, 35,245,157 and 32,010,375 outstanding as of December 31, 2016 and 2015, respectively	`CommonStockValue`	$46.00K	USD	Point-in-time
Common stock, $0.01 par value; 50,000,000 shares authorized, 35,570,157 and 32,010,375 shares issued, 35,245,157 and 32,010,375 outstanding as of December 31, 2016 and 2015, respectively	`CommonStockValue`	$355.70K	USD	Point-in-time
Common stock, $0.01 par value; 50,000,000 shares authorized, 35,570,157 and 32,010,375 shares issued, 35,245,157 and 32,010,375 outstanding as of December 31, 2016 and 2015, respectively	`CommonStockValue`	$320.10K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$9.07M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$8.37M	USD	Point-in-time
Accumulated (deficit)	`RetainedEarningsAccumulatedDeficit`	$-8.59M	USD	Point-in-time
Accumulated (deficit)	`RetainedEarningsAccumulatedDeficit`	$-9.69M	USD	Point-in-time
Equity	`Equity`	$100.08K	USD	Point-in-time
Equity	`Equity`	$-268.12K	USD	Point-in-time
Treasury stock, 325,000 shares, at cost	`TreasuryStockValue`	$87.05K	USD	Point-in-time
Treasury stock, 325,000 shares, at cost	`TreasuryStockValue`	-	USD	Point-in-time
Total Immudyne, Inc. Stockholders' Equity (Deficit)	`StockholdersEquity`	$100.08K	USD	Point-in-time
Total Immudyne, Inc. Stockholders' Equity (Deficit)	`StockholdersEquity`	$-355.17K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$80.91K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$-6.55K	USD	Point-in-time
Total Stockholders' Equity (Deficit)	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$180.99K	USD	Point-in-time
Total Stockholders' Equity (Deficit)	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-139.50K	USD	Point-in-time
Total Stockholders' Equity (Deficit)	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-361.73K	USD	Point-in-time
Total Liabilities and Stockholders' Equity (Deficit)	`LiabilitiesAndStockholdersEquity`	$448.47K	USD	Point-in-time
Total Liabilities and Stockholders' Equity (Deficit)	`LiabilitiesAndStockholdersEquity`	$789.82K	USD	Point-in-time

Income Statement 40 line items

Line Item	Tag	Value	Unit	Period
Net sales	`Revenues`	$5.24M	USD	Annual
Net sales	`Revenues`	$1.22M	USD	Annual
Cost of sales	`CostOfRevenue`	$247.77K	USD	Annual
Cost of sales	`CostOfRevenue`	$1.95M	USD	Annual
Gross Profit	`GrossProfit`	$3.29M	USD	Annual
Gross Profit	`GrossProfit`	$971.09K	USD	Annual
Compensation and related expenses	`CompensationAndRelatedExpenses`	$532.42K	USD	Annual
Compensation and related expenses	`CompensationAndRelatedExpenses`	$1.25M	USD	Annual
Professional fees	`ProfessionalFees`	$477.40K	USD	Annual
Professional fees	`ProfessionalFees`	$114.89K	USD	Annual
Marketing expenses	`MarketingExpense`	$1.71M	USD	Annual
Marketing expenses	`MarketingExpense`	$230.66K	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpense`	-	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpense`	$23.93K	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$331.41K	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.03M	USD	Annual
Total operating expenses	`OperatingExpenses`	$1.23M	USD	Annual
Total operating expenses	`OperatingExpenses`	$4.47M	USD	Annual
Operating (Loss)	`OperatingIncomeLoss`	$-1.17M	USD	Annual
Operating (Loss)	`OperatingIncomeLoss`	$-262.22K	USD	Annual
Gain on sale of Adiuvo Investment S.A. stock	`GainOnSaleOfInvestments`	-	USD	Annual
Gain on sale of Adiuvo Investment S.A. stock	`GainOnSaleOfInvestments`	$127.26K	USD	Annual
Interest (expense)	`InterestExpense`	$48.61K	USD	Annual
Interest (expense)	`InterestExpense`	$37.48K	USD	Annual
Net Income (Loss) Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.22M	USD	Annual
Net Income (Loss) Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-172.43K	USD	Annual
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	Annual
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-13.20K	USD	Annual
Net (Loss)	`ProfitLoss`	$-159.23K	USD	Annual
Net (Loss)	`ProfitLoss`	$-1.22M	USD	Annual
Net (loss) attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-115.75K	USD	Annual
Net (loss) attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-97.24K	USD	Annual
Net (loss) attributable to Immudyne, Inc.	`NetIncomeLoss`	$-1.11M	USD	Annual
Net (loss) attributable to Immudyne, Inc.	`NetIncomeLoss`	$-61.99K	USD	Annual
Basic and diluted (loss) per share attributable to Immudyne, Inc.	`EarningsPerShareBasicAndDiluted`	-	USD	Annual
Basic and diluted (loss) per share attributable to Immudyne, Inc.	`EarningsPerShareBasicAndDiluted`	$-0.03	USD	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	33.48M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	30.81M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	33.48M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	30.81M	shares	Annual

Cash Flow Statement 64 line items

Line Item	Tag	Value	Unit	Period
Net (Loss)	`ProfitLoss`	$-159.23K	USD	Annual
Net (Loss)	`ProfitLoss`	$-1.22M	USD	Annual
Depreciation	`Depreciation`	$43.75K	USD	Annual
Depreciation	`Depreciation`	-	USD	Annual
Bad debt provision	`ProvisionForDoubtfulAccounts`	-	USD	Annual
Bad debt provision	`ProvisionForDoubtfulAccounts`	$71.14K	USD	Annual
Amortization of debt discount	`AmortizationOfDebtDiscountPremium`	$33.72K	USD	Annual
Amortization of debt discount	`AmortizationOfDebtDiscountPremium`	-	USD	Annual
Deferred tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	Annual
Deferred tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-13.20K	USD	Annual
Stock compensation expense	`ShareBasedCompensation`	$587.99K	USD	Annual
Stock compensation expense	`ShareBasedCompensation`	$77.30K	USD	Annual
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	Annual
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$65.00K	USD	Annual
Gain on sale of Adiuvo Investment S.A. stock	`GainLossOnSaleOfInvestments`	$127.26K	USD	Annual
Gain on sale of Adiuvo Investment S.A. stock	`GainLossOnSaleOfInvestments`	-	USD	Annual
Trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$139.47K	USD	Annual
Trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$361.44K	USD	Annual
Other receivables	`IncreaseDecreaseInOtherReceivables`	$2.25K	USD	Annual
Other receivables	`IncreaseDecreaseInOtherReceivables`	-	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$99.22K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$20.04K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$-21.97K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$585.45K	USD	Annual
Net cash (used) by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-407.91K	USD	Annual
Net cash (used) by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-295.12K	USD	Annual
Proceeds from sale of Adiuvo Investment S.A. stock	`PaymentsForProceedsFromInvestments`	$-127.26K	USD	Annual
Proceeds from sale of Adiuvo Investment S.A. stock	`PaymentsForProceedsFromInvestments`	-	USD	Annual
Investment in subsidiary by noncontrolling interest	`ProceedsFromPaymentsToMinorityShareholders`	$219.89K	USD	Annual
Investment in subsidiary by noncontrolling interest	`ProceedsFromPaymentsToMinorityShareholders`	$178.15K	USD	Annual
Increase in notes payable	`IncreaseDecreaseInNotesPayableCurrent`	$200.00K	USD	Annual
Increase in notes payable	`IncreaseDecreaseInNotesPayableCurrent`	$305.00K	USD	Annual
Proceeds from convertible note payable	`ProceedsFromConvertibleDebt`	-	USD	Annual
Proceeds from convertible note payable	`ProceedsFromConvertibleDebt`	$100.00K	USD	Annual
Repayment of notes payable	`RepaymentsOfNotesPayable`	$147.00K	USD	Annual
Repayment of notes payable	`RepaymentsOfNotesPayable`	$168.60K	USD	Annual
Proceeds from options exercise	`ProceedsFromStockOptionsExercised`	$30.00K	USD	Annual
Proceeds from options exercise	`ProceedsFromStockOptionsExercised`	-	USD	Annual
Sale of common stock and warrants	`IssuanceOfCommonStockAndWarrants`	-	USD	Annual
Sale of common stock and warrants	`IssuanceOfCommonStockAndWarrants`	$63.25K	USD	Annual
Purchase of treasury stock	`ProceedsFromIssuanceOfCommonStock`	$-10.80K	USD	Annual
Purchase of treasury stock	`ProceedsFromIssuanceOfCommonStock`	$-87.05K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$357.49K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$325.35K	USD	Annual
Net (decrease) increase in cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$157.49K	USD	Annual
Net (decrease) increase in cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-50.42K	USD	Annual
Cash at beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$73.86K	USD	Point-in-time
Cash at beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$232.98K	USD	Point-in-time
Cash at beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$75.50K	USD	Point-in-time
Cash at beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$182.56K	USD	Point-in-time
Cash at end of the year	`CashAndCashEquivalentsAtCarryingValue`	$73.86K	USD	Point-in-time
Cash at end of the year	`CashAndCashEquivalentsAtCarryingValue`	$232.98K	USD	Point-in-time
Cash at end of the year	`CashAndCashEquivalentsAtCarryingValue`	$75.50K	USD	Point-in-time
Cash at end of the year	`CashAndCashEquivalentsAtCarryingValue`	$182.56K	USD	Point-in-time
Cash paid during the period for interest	`InterestPaid`	$28.98K	USD	Annual
Cash paid during the period for interest	`InterestPaid`	$13.65K	USD	Annual
Issuance of company stock for notes and other payables	`ConversionOfStockAmountIssued1`	-	USD	Annual
Issuance of company stock for notes and other payables	`ConversionOfStockAmountIssued1`	$170.07K	USD	Annual
Issuance of common stock in relation to debt offering	`IssuanceOfCommonStockInRelationToDebtOffering`	$58.75K	USD	Annual
Issuance of common stock in relation to debt offering	`IssuanceOfCommonStockInRelationToDebtOffering`	-	USD	Annual
Reclassification of options, warrants and other contracts from equity to derivative liabilities	`ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities`	$192.25K	USD	Annual
Reclassification of options, warrants and other contracts from equity to derivative liabilities	`ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities`	-	USD	Annual
Conversion of equity invested in subsidiary to common stock and warrants	`ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants`	-	USD	Annual
Conversion of equity invested in subsidiary to common stock and warrants	`ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants`	$100.00K	USD	Annual

Stockholders Equity 29 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$180.99K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-139.50K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-361.73K	USD	Point-in-time
Amortization of stock options	`AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions`	$120.87K	USD	Annual
Amortization of stock options	`AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions`	$22.30K	USD	Annual
Purchase of company stock	`StockRepurchasedAndRetiredDuringPeriodValue`	$-10.80K	USD	Annual
Issuance of company stock for notes and other payables	`StockIssuedDuringPeriodValueOther`	$170.07K	USD	Annual
Issuance of common stock for services	`StockIssuedDuringPeriodValueIssuedForServices`	$383.33K	USD	Annual
Issuance of common stock for services	`StockIssuedDuringPeriodValueIssuedForServices`	$65.00K	USD	Annual
Extension of option and warrant expiration dates	`Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates`	$55.00K	USD	Annual
Sale of common stock and warrants	`StockIssuedDuringPeriodValueNewIssues`	$63.25K	USD	Annual
Conversion of NCI equity for shares, value	`StockIssuedDuringPeriodValueConversionOfUnits`	$100.00K	USD	Annual
Issuance of common stock for options exercise	`StockIssuedDuringPeriodValueStockOptionsExercised`	$30.00K	USD	Annual
Issued of common stock, value	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$58.75K	USD	Annual
Issued of common stock, value	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$58.75K	USD	Point-in-time
Issuance of common stock in relation to debt offering, shares	`StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities`	62,500.00	shares	1 Quarter
Issuance of common stock in relation to debt offering, shares	`StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities`	250,000.00	shares	Point-in-time
Issuance of warrants for services	`AdjustmentOfWarrantsGrantedForServices`	$20.59K	USD	Annual
Issuance of warrants for services	`AdjustmentOfWarrantsGrantedForServices`	-	USD	Annual
Purchase of treasury stock	`TreasuryStockValueAcquiredCostMethod`	$-87.05K	USD	Annual
Issuance of stock options for services	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition`	$63.21K	USD	Annual
Investment in subsidiary by noncontrolling interest	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$119.89K	USD	Annual
Investment in subsidiary by noncontrolling interest	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$178.15K	USD	Annual
Reclassification of options, warrants and other contracts from equity to derivative liabilities	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities`	$-192.25K	USD	Annual
Net (Loss)	`ProfitLoss`	$-159.23K	USD	Annual
Net (Loss)	`ProfitLoss`	$-1.22M	USD	Annual
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$180.99K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-139.50K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-361.73K	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.